enGene Therapeutics Inc. (ENGN) shareholders
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Forbion Growth Management B.V. Joint filing with Forbion Growth Opportunities Fund I Cooperatief U.A (17.20%), Forbion Growth Sponsor FEAC I B.V. (10.40%) | 9,201,434 | 17.20% | 13D (active) amendment | Oct 30, 2024 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 6,899,803 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 6,770,605 | 9.99% | 13G (passive) | Nov 11, 2025 |
| BML Investment Partners, L.P. | 6,669,908 | 9.95% | 13G (passive) amendment | May 12, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.20%), Invus Public Equities Advisors, LLC (8.20%) and 2 more | 6,256,662 | 9.30% | 13G (passive) amendment | Jun 30, 2026 |
| VHCP Management III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 5,046,414 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Kynam Capital Management, LP Joint filing with Kynam Capital Management GP, LLC (9.80%), Yue Tang (9.80%) | 4,994,090 | 9.80% | 13G (passive) | Dec 31, 2024 |
| Venrock Healthcare Capital Partners EG, L.P. Joint filing with Venrock Healthcare Capital Partners III, L.P. (7.10%), VHCP Co-Investment Holdings III, LLC (7.10%) and 4 more | 4,771,414 | 7.10% | 13G (passive) amendment | Dec 31, 2025 |
| Benjamin Rovinski Joint filing with Lumira Capital Investment Management Inc. (9.60%), Peter van der Velden (9.60%) and 4 more | 4,181,853 | 9.60% | 13D (active) amendment | Feb 20, 2024 |
| Cormorant Asset Management, LP Joint filing with Bihua Chen (5.97%) | 4,000,000 | 5.97% | 13G (passive) | Dec 31, 2025 |
| Forbion Capital Fund III Coöperarief U.A | 3,369,275 | – | 13G (passive) amendment | Dec 31, 2023 |
| Anders Hove | 3,357,282 | 5.00% | 13G (passive) | Jul 20, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (5.90%), Lampert Mark N (5.90%) and 1 more | 3,051,439 | 5.90% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 6,669,908 | – | $11.54M | New | 6.55% |
| Siren, L.L.C. | 6,256,662 | – | $10.82M | New | 0.22% |
| Perceptive Advisors LLC | 4,822,169 | – | $8.34M | New | 0.13% |
| Ameriprise Financial Inc | 2,675,876 | – | $4.63M | New | 0.00% |
| Nextech Invest, Ltd. | 2,324,943 | – | $4.02M | New | 0.19% |
| ADAR1 Capital Management, LLC | 2,104,986 | – | $3.64M | New | 0.17% |
| Vestal Point Capital, LP | 1,667,430 | – | $2.88M | New | 0.07% |
| Acorn Capital Advisors, LLC | 1,271,257 | – | $2.20M | New | 0.60% |
| Peapod Lane Capital LLC | 1,102,149 | – | $1.91M | New | 1.29% |
| Balyasny Asset Management L.P. | 1,007,344 | – | $1.74M | New | 0.00% |
| Millennium Management LLC | 966,627 | – | $1.67M | New | 0.00% |
| Renaissance Technologies LLC | 829,700 | – | $1.44M | New | 0.00% |
| Citadel Advisors LLC | 717,686 | – | $1.24M | New | 0.00% |
| Affinity Asset Advisors, LLC | 600,000 | – | $1.04M | New | 0.05% |
| UBS Group AG | 509,087 | – | $880.72K | New | 0.00% |
| Eversept Partners, LP | 469,584 | – | $812.38K | New | 0.04% |
| Kynam Capital Management, LP | 457,855 | – | $792.09K | New | 0.04% |
| Seven Fleet Capital Management LP | 411,065 | – | $711.14K | New | 0.12% |
| Jane Street Group, LLC | 382,459 | – | $661.65K | New | 0.00% |
| Rangeley Capital, LLC | 305,102 | – | $527.83K | New | 0.48% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 56 | 38M | 55 / 0 | 0 / 1 | 38M | 0M |
| Q1 2026 | 2 | 0M | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ENGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 40,733 | – | $75.36K | 0.00% | May 31, 2026 |
| Tiff Multi-Asset Fund | 10,639 | – | $18.41K | 0.00% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 9,974 | – | $17.26K | 0.00% | Jun 30, 2026 |
| North Square Kennedy Microcap Fund | 7,649 | – | $14.15K | 0.04% | May 31, 2026 |
| AST Small-Cap Equity Portfolio | 1,376 | – | $2.38K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| William Grossman | Interim Chief Medical Officer, Director | 5,102 | Sep 24, 2026 |
| Ronald Harold Wilfred Cooper | CEO & President, Director | 10,000 | Feb 3, 2026 |
| Jason Duncan | Chief Legal & Admin Officer | 0 | Nov 13, 2026 |
| Constantine Chinoporos | Interim Chief Business Officer | – | Jul 22, 2026 |
| Kathleen P. Richton | SVP, Finance and Treasurer | 6,900 | Jul 22, 2026 |
| Anthony Tzeyew Cheung | Chief Scientific Officer | 102,873 | Feb 3, 2026 |
| Jill Buck | Chief Development Officer | – | Feb 3, 2026 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | – | Feb 3, 2026 |
| D. Ryan Daws | Chief Financial Officer | – | Feb 3, 2026 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | – | Feb 3, 2026 |
| Joan Connolly | Chief Technology Officer | – | Feb 3, 2026 |
| Matthew Ross Boyd | Chief Regulatory Officer | 7,500 | Feb 3, 2026 |
| Hussein Sweiti | Chief Medical Officer | – | Oct 1, 2025 |
| Amy Pott | Chief Global Comm. Ofc. | – | Jun 16, 2025 |
| Raj Som Pruthi | Chief Medical Officer | – | Jan 31, 2025 |
| Paul J. Hastings | Director | – | Jun 17, 2026 |
| Lota S. Zoth | Director | – | Jun 17, 2026 |
| Wouter Joustra | Director | – | Jun 17, 2026 |
| Gerald A. Brunk | Director | 238,851 | Jun 17, 2026 |
| Philip Astley-Sparke | Director | 20,000 | Jun 17, 2026 |
| Richard M. Glickman | Director | 24,675 | Jun 17, 2026 |
| Michael Thomas Heffernan | Director | – | Jun 17, 2026 |
| Jasper Bos | Director | – | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| William Grossman Interim Chief Medical Officer, Director | Sep 22, 2026 | Buy | +5,102 | $1.97 | $10.05K | 5,102 |
| Growth Management B.V. Forbion 10% owner | Oct 30, 2024 | Buy | +561,797 | $8.90 | $5.00M | 3,032,430 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 8, 2024 | Buy | +800 | $6.60 | $5.28K | 2,470,633 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 7, 2024 | Buy | +11,844 | $6.55 | $77.58K | 2,469,833 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 4, 2024 | Buy | +5,997 | $6.54 | $39.22K | 2,457,989 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 3, 2024 | Buy | +5,769 | $6.48 | $37.38K | 2,451,992 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 2, 2024 | Buy | +10,153 | $6.37 | $64.67K | 2,446,223 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Oct 1, 2024 | Buy | +35,279 | $6.44 | $227.20K | 2,436,070 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Sep 30, 2024 | Buy | +341,332 | $6.34 | $2.16M | 2,400,791 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Sep 27, 2024 | Buy | +3,243 | $6.38 | $20.69K | 2,059,459 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Sep 27, 2024 | Buy | +38,396 | $5.94 | $228.07K | 2,056,216 |
| Ronald Harold Wilfred Cooper Chief Executive Officer, Director | Sep 27, 2024 | Buy | +10,000 | $5.70 | $57.00K | 10,000 |
| Richard M. Glickman Director | May 28, 2024 | Option exercise | +120 | $0.89 | $107 | 24,675 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Apr 22, 2024 | Sale | −47,854 | $15.00 | $717.81K | 3,036,153 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Apr 19, 2024 | Sale | −100 | $15.00 | $1.50K | 3,084,007 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Apr 18, 2024 | Sale | −4,575 | $15.01 | $68.67K | 3,084,107 |
| Anthony Tzeyew Cheung Chief Technology Officer | Mar 18, 2024 | Option exercise | +52,940 | $0.89 | $47.12K | 102,873 |
| Capital Investment Management Inc. Lumira 10% owner | Feb 20, 2024 | Award | +644,965 | $10.00 | $6.45M | 993,651 |
| Capital Investment Management Inc. Lumira 10% owner | Feb 20, 2024 | Award | +155,035 | $10.00 | $1.55M | 238,851 |
| Gerald A. Brunk Director, 10% owner | Feb 20, 2024 | Award | +155,035 | $10.00 | $1.55M | 238,851 |
| Gerald A. Brunk Director, 10% owner | Feb 20, 2024 | Award | +644,965 | $10.00 | $6.45M | 993,651 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Dec 29, 2023 | Buy | +9,620 | $9.09 | $87.45K | 2,017,820 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Dec 29, 2023 | Buy | +400 | $8.30 | $3.32K | 2,008,200 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Dec 28, 2023 | Buy | +5,050 | $7.69 | $38.83K | 2,007,800 |
| Growth Opportunities Fund I. Cooperatief U.A. Forbion 10% owner | Dec 27, 2023 | Buy | +2,750 | $7.17 | $19.72K | 2,002,750 |
| Anthony Tzeyew Cheung Chief Technology Officer | Oct 31, 2023 | Award | +49,933 | – | – | 49,933 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +44,647 | – | – | 44,647 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +348,686 | – | – | 348,686 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +83,816 | – | – | 83,816 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +1,341,790 | – | – | 1,341,790 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +1,077,386 | – | – | 1,077,386 |
| Gerald A. Brunk Director, 10% owner | Oct 31, 2023 | Award | +152,974 | – | – | 152,974 |
| Growth Sponsor FEAC I. B.V. Forbion 10% owner | Oct 31, 2023 | Other | +130,085 | – | – | 1,503,581 |
| Growth Sponsor FEAC I. B.V. Forbion 10% owner | Oct 31, 2023 | Other | +2,262,351 | – | – | 3,765,932 |
| Richard M. Glickman Director | Oct 31, 2023 | Award | +24,555 | – | – | 24,555 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of enGene Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 41,009 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?